PCVX | Ticker Profile - Titan Protect

PCVX

Vaxcyte, Inc.

Healthcare · Biotechnology · NMS

$47.36

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$7.4B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.87

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-30.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$110.00

+132% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

https://vaxcyte.com

Country: United States Employees: 507 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.133

Positive but modest risk-adjusted returns

Kelly Fraction

0.0098

Marginal edge — very small allocation suggested

Calmar Ratio

-0.175

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-13.4%

Historical annualised return based on price data

Max Drawdown

-76.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

236

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.30

Moves slightly more than the broader market

52W High

$65.00

27% below the year high

52W Low

$29.08

63% above the year low

Avg Volume

1,407,103

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

9.6%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-6.89

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.88

Heavy leverage — higher financial risk if revenues decline

Current Ratio

7.49

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

7.18

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-439,788,512

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-946,531,968

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$163.00

Target Median

$110.00

Target Low

$67.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
7 Feb2025	Tim Walberg	Republican	buy	15K–50K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go